APYX Stock Forecast & Price Target

Apyx Medical Corp is experiencing robust growth in its Surgical Aesthetics segment, with projected revenue of $43.0 million to $45.0 million for the upcoming period, reflecting a year-over-year increase of approximately 14% at the midpoint of guidance. The company's improved execution and positive demand trends have led to an upward revision in full-year revenue guidance to a range of $50.5 million to $52.5 million, with expectations that Surgical Aesthetics will drive most of this growth. Additionally, a notable 12% increase in quarterly revenue to $12.9 million was achieved, largely fueled by the successful launch of the AYON Body Contouring System and increased sales of single-use handpieces.

Apyx Medical Corp is experiencing significant challenges reflected in its revised guidance for Original Equipment Manufacturing (OEM) sales, which are expected to decrease to approximately $7.5 million, marking a $0.5 million reduction from prior forecasts. The company's stock performance has been adversely impacted by an FDA warning letter issued in March 2022, compounded by increased competition and pressures in the cash-pay aesthetics market, further diminishing investor confidence. Additionally, a decline in cash reserves, from $29.3 million to $25.1 million in the third quarter of 2025, raises concerns about the company's financial stability and its ability to fund future growth initiatives.